We provide tailored support to Biotech companies of every stage to bring life-changing therapies to patients
We provide investors with comprehensive CMC, scientific, regulatory, and clinical due diligence packages for biotech startups.
Our expert team ensures that your investment is de-risked by evaluating the feasibility, regulatory compliance, and cost-effectiveness of new assets, pipelines and technology platforms.
We partner with early-stage biotech founders to support them in building and growing their businesses. Our full-time or fractional support fills critical biotech skill gaps, helping you achieve meaningful milestones without depleting precious capital.
We have stood in your shoes and have been part of successful exits, bringing invaluable experience to your journey.
We understand the unique challenges faced by biotech companies at different stages of development.
Our consultancy services provide comprehensive support, whether you need us to undertake large projects or step in ad hoc to address specific needs.
Our founding team
We built our experience in prestigious companies to include CRISPR, GammaDelta, Oxford Biomedica, Lonza, NightStar, Takeda and Biogen. We are supported by a team of trusted experts and former colleagues to bring CMC, Programme, Regulatory, Clinical, IT and Lab support.
How can we help you meet your goals?
Evi Dimitriadou
Evi’s career, which spans near two decades, started with successfully developing platforms for difficult-to-manufacture biologics. Her passion for innovation led her into technology evaluation and development of a personalised medicine platform. Over the last 10 years, Evi has leveraged her scientific background in Programme and Portfolio management in biotech startup, global CDMO and Big Pharma environments, each requiring tailored approaches. She helps biotech companies make holistic and healthy decisions and make breakthrough therapies possible through solid planning and execution.
Mardon McFarlane
Mardon brings almost two decades of experience in the biotech industry having biologics (recombinant proteins, antibodies) and cell and gene therapy (viral vectors, CAR Ts and CRISPR mediated therapies) experience. He has enjoyed developing and leading process development and manufacturing activities for many modalities. Having worked on more than 20 IND/CTA submissions and two first-in-class BLA candidates, Mardon has a deep understanding of the current CMC challenges and opportunities and is passionate about translating excellent science into accessible therapies.
Get in touch & book a free Consultation
Registered Number: 15342729, TaxoBioscience 2024. All Rights Reserved
Suite 73, 4 Spring Bridge Road, London, W5 2AA
Privacy Policy